Overview

Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to tamoxifen resistance. PURPOSE: This laboratory study is looking at tamoxifen resistance in women with stage I, stage II, stage IIIA, or stage IIIB breast cancer.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Comprehensive Cancer Center of Wake Forest University
Wake Forest University Health Sciences
Collaborator:
National Cancer Institute (NCI)
Treatments:
Tamoxifen
Criteria
Inclusion Criteria:

- Histologically confirmed invasive breast cancer

- Initial pathologic stage I-IIIB disease

- No stage IV disease

- Meets the following criteria for breast cancer therapy:

- Received prior primary local therapy for breast cancer

- Scheduled to begin tamoxifen citrate as adjuvant therapy for breast cancer within
3 weeks

- Hormone receptor status:

- Estrogen-receptor positive tumor

- Female

- Pre- or post-menopausal

- Must be able to donate 20 mL of blood

Exclusion Criteria:

- Severe anemia, defined as hemoglobin < 11 g/dL

- Psychiatric history that would preclude obtaining informed consent